Compare FTFT & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | BRTX |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 9.3M |
| IPO Year | 2008 | 2015 |
| Metric | FTFT | BRTX |
|---|---|---|
| Price | $1.63 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.14 | ★ 66.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,158,125.00 | $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.21 |
| 52 Week High | $4.03 | $2.28 |
| Indicator | FTFT | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 13.02 |
| Support Level | $1.42 | $0.22 |
| Resistance Level | $1.74 | $0.29 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 35.08 | 2.93 |
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.